GSK and Theravance submit Anoro to FDA as COPD drug

02/20/2013 | American City Business Journals

GlaxoSmithKline and Theravance said the FDA has accepted their new drug application for Anoro as a daily treatment for chronic obstructive pulmonary disease. Anoro, formerly known as UMEC/VI, is a combination of umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta-2 agonist. The FDA is expected to decide by Dec. 18.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY